Delfi Liquid Biopsy Shows Promise for Reducing Lung Cancer Deaths

Excerpt from the Press Release:

BALTIMORE and PALO ALTO, Calif., Aug. 20, 2021 /PRNewswire/ — A novel machine learning based blood testing technology that could help to increase detection of early-stage lung cancer demonstrated promising results in a study published in Nature Communications¹. Delfi Diagnostics Inc.’s lung cancer screening technology, which uses advanced machine learning algorithms to analyze genome-wide cell-free DNA fragmentation profiles, was able to detect approximately 90% of cancer cases in a group of nearly 800 individuals who underwent lung cancer screening with a low-dose CT (LDCT) scan.

Lung cancer is the leading cause of cancer deaths, with the vast majority of lung cancers detected at late stages when prognosis is poor. LDCT scans have proven to be effective in lowering overall mortality among those at high risk for developing the disease, by detecting cancer early. Recently, the USPSTF expanded its existing lung screening guidance to include high risk individuals 50 years old and over, increasing the recommended population to 15 million U.S. adults.

Click the button below to read the entire Press Release:

Continue Reading The Press Release